1	A Multi-Center Randomized, Double-Blind, Placebo Controlled,
2	Parallel Group, Phase IIa Study to Evaluate the Efficacy, Safety and
3	Tolerability of an Anthocyanin Rich Extract (ACRE) in Patients with
4	Ulcerative Colitis
5	Luc Biedermann <sup>1†</sup> , Michael Doulberis <sup>1,2,3†</sup> , Philipp Schreiner <sup>1</sup> , Ole
6	Haagen Nielsen <sup>4</sup> , Frans Olivier The <sup>1</sup> , Stephan Brand <sup>5</sup> , Sabine Burk <sup>1</sup> ,
7	Petr Hruz <sup>6</sup> , Pascal Juillerat <sup>7</sup> , Claudia Krieger – Grübel⁵, Kristin Leu¹,
8	Gabriel Leventhal, <sup>1</sup> Benjamin Misselwitz <sup>7</sup> , Sylvie Scharl <sup>1</sup> , Alain
٥	Schoepfer <sup>8</sup> . Frank Seibold <sup>9</sup> . Hans Herfarth <sup>10*</sup> Gerhard Rogler <sup>1*<sup>11</sup></sup>
9	
10	<sup>1</sup> Department of Gastroenterology & Hepatology, University Hospital Zurich, University of Zurich,
9 10 11	<sup>1</sup> Department of Gastroenterology & Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland <u>luc.biedermann@usz.ch</u> , <u>philippschreiner@hotmail.com</u> , <u>sabine.burk@usz.ch</u>
10 11 12	<sup>1</sup> Department of Gastroenterology & Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland <u>luc.biedermann@usz.ch</u> , <u>philippschreiner@hotmail.com</u> , <u>sabine.burk@usz.ch</u> <u>gabriel@leventhal.ch</u> , <u>Sylvie.Scharl@usz.ch</u> , <u>Gerhard.rogler@usz.ch</u> ,
10 11 12 13	<sup>1</sup> Department of Gastroenterology & Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland <u>luc.biedermann@usz.ch</u> , <u>philippschreiner@hotmail.com</u> , <u>sabine.burk@usz.ch</u> <u>gabriel@leventhal.ch</u> , <u>Sylvie.Scharl@usz.ch</u> , <u>Gerhard.rogler@usz.ch</u> , <u>fransolivier.the@triemli.zuerich.ch</u> , <u>leu.kristin@gmail.com</u>
10 11 12 13 14	<sup>1</sup> Department of Gastroenterology & Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland <u>luc.biedermann@usz.ch</u> , <u>philippschreiner@hotmail.com</u> , <u>sabine.burk@usz.ch</u> <u>gabriel@leventhal.ch</u> , <u>Sylvie.Scharl@usz.ch</u> , <u>Gerhard.rogler@usz.ch</u> , <u>fransolivier.the@triemli.zuerich.ch</u> , <u>leu.kristin@gmail.com</u> <sup>2</sup> Gastroklinik, Private Gastroenterological Practice, Horgen, Switzerland. <u>doulberis@gmail.com</u>
10 11 12 13 14 15	<sup>1</sup> Department of Gastroenterology & Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland <u>luc.biedermann@usz.ch</u> , <u>philippschreiner@hotmail.com</u> , <u>sabine.burk@usz.ch</u> gabriel@leventhal.ch, <u>Sylvie.Scharl@usz.ch</u> , <u>Gerhard.rogler@usz.ch</u> , <u>fransolivier.the@triemli.zuerich.ch</u> , leu.kristin@gmail.com <sup>2</sup> Gastroklinik, Private Gastroenterological Practice, Horgen, Switzerland. <u>doulberis@gmail.com</u> <sup>3</sup> Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau,
10 11 12 13 14 15 16	<sup>1</sup> Department of Gastroenterology & Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland <u>luc.biedermann@usz.ch</u> , philippschreiner@hotmail.com, sabine.burk@usz.ch gabriel@leventhal.ch, Sylvie.Scharl@usz.ch, Gerhard.rogler@usz.ch, fransolivier.the@triemli.zuerich.ch, leu.kristin@gmail.com <sup>2</sup> Gastroklinik, Private Gastroenterological Practice, Horgen, Switzerland. <u>doulberis@gmail.com</u> <sup>3</sup> Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau, Aarau, Switzerland.
10 11 12 13 14 15 16 17	<sup>1</sup> Department of Gastroenterology & Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland <u>luc.biedermann@usz.ch</u> , philippschreiner@hotmail.com, sabine.burk@usz.ch gabriel@leventhal.ch, <u>Sylvie.Scharl@usz.ch</u> , <u>Gerhard.rogler@usz.ch</u> , fransolivier.the@triemli.zuerich.ch, leu.kristin@gmail.com <sup>2</sup> Gastroklinik, Private Gastroenterological Practice, Horgen, Switzerland. <u>doulberis@gmail.com</u> <sup>3</sup> Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau, Aarau, Switzerland.
10 11 12 13 14 15 16 17 18	<ul> <li><sup>1</sup>Department of Gastroenterology &amp; Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland luc.biedermann@usz.ch, philippschreiner@hotmail.com, sabine.burk@usz.ch gabriel@leventhal.ch, Sylvie.Scharl@usz.ch, Gerhard.rogler@usz.ch, fransolivier.the@triemli.zuerich.ch, leu.kristin@gmail.com</li> <li><sup>2</sup>Gastroklinik, Private Gastroenterological Practice, Horgen, Switzerland. doulberis@gmail.com</li> <li><sup>9</sup>Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau, Aarau, Switzerland.</li> <li><sup>4</sup>Department of Gastroenterology, Herlev and Gentofte Hospital, University of Copenhagen, 2730 Herlev, Denmark <u>ole.haagen.nielsen@regionh.dk</u></li> </ul>
10 11 12 13 14 15 16 17 18 19	<ul> <li><sup>1</sup>Department of Gastroenterology &amp; Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland <u>luc.biedermann@usz.ch</u>, <u>philippschreiner@hotmail.com</u>, <u>sabine.burk@usz.ch</u></li> <li>gabriel@leventhal.ch, <u>Sylvie.Scharl@usz.ch</u>, <u>Gerhard.rogler@usz.ch</u>, fransolivier.the@triemli.zuerich.ch, leu.kristin@gmail.com</li> <li><sup>2</sup>Gastroklinik, Private Gastroenterological Practice, Horgen, Switzerland. <u>doulberis@gmail.com</u></li> <li><sup>3</sup>Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau, Aarau, Switzerland.</li> <li><sup>4</sup>Department of Gastroenterology, Herlev and Gentofte Hospital, University of Copenhagen, 2730 Herlev, Denmark <u>ole.haagen.nielsen@regionh.dk</u></li> <li><sup>5</sup>Department of Gastroenterology and Hepatology, Kantonsspital St. Gallen, 9007 St. Gallen,</li> </ul>

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 21 <sup>6</sup>Department of Gastroenterology, Clarunis University Center for Gastrointestinal and Liver
- 22 Diseases, 4052 Basel, Switzerland petr.hruz@clarunis.ch
- 23 Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of
- 24 Bern, 3010 Bern, Switzerland <u>pascal.juillerat@insel.ch</u>, <u>benjamin.misselwitz@insel.ch</u>
- 25 <sup>8</sup>Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and
- 26 University of Lausanne, 1011 Lausanne, Switzerland <u>alain.schoepfer@chuv.ch</u>
- 27 °Cabinet de Gastroentérologie, Balsiger, Seibold & Partenaires, Villars-sur-Glâne, 1752 Fribourg,
- 28 Switzerland <u>frank.seibold@magendarmsuisse.ch</u>
- 29 <sup>10</sup>University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology, NC
- 30 27514 Chapel Hill, NC, USA <u>hans\_herfarth@med.unc.edu</u>
- 31 † Sharing equally first position
- 32 \* Sharing equally last position
- 33
- **34 Short title:** ACRE for active refractory ulcerative colitis
- 35

36 Corresponding author: Prof. Gerhard Rogler MD, PhD, Chief and Chairman of
37 Department of Gastroenterology and Hepatology, University Hospital Zurich, Raemistrasse
38 100, 8091 Zurich, Switzerland. Phone +41 44 255 24 01. E-mail: Gerhard.rogler@usz.ch
39
40 Funding: This work was supported by grants from the Swiss National Science Foundation

41 (SNF) to GR [Grant No. 33IC30\_166844] and the Litwin Foundation (New Hyde Park, NY).

## 42 Clinicaltrials.gov number: NCT04000139

- 43 Ethical approval number: BASEC2017-00156
- 44 **Informed consent statement:** All patients signed an informed consent form
- 45 Data availability statement: Data available on request due to privacy/ethical restrictions
- 46 **Conflicts of interest:**
- 47 PS received consulting fees from Pfizer, Abbvie, Takeda and Janssen-Cilag and travel
- 48 support from Falk, UCB and Pfizer.

49 LB reports fees for consulting/advisory board from Abbvie, MSD, Vifor, Falk, Esocap,

- 50 Calypso, Ferring, Pfizer, Shire, Takeda, Janssen, Ewopharma.
- 51 GR declares consulting fees from Abbvie, Augurix, BMS, Boehringer, Calypso, Celgene,
- 52 FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche,
- 53 UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; speaker's honoraria from Astra
- 54 Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor and Zeller;
- 55 and grants support from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD,
- 56 Novartis, Pfizer, Roche, Takeda, Tillots, UCB and Zeller.
- 57 BM reports traveling fees from Takeda, Vifor, Gilead and MSD. BM received fees as a
- 58 speaker from Takeda. BM has served at an advisory board for Gilead, Takeda and BMS. BM
- 59 has received research grants from MSD and BMS unrelated to the submitted work.
- 60 MD reports traveling fees from Takeda, FALK, Abbvie as well as consulting fees from61 Takeda.
- 62 Rest of the authors declare no compelling conflict of interests.
- 63

### 64 Abstract

Background: In an open label pilot study dried bilberries were effective in inducing
clinical, endoscopic and biochemical improvement in ulcerative colitis (UC) patients.
Aim was the investigation of efficacy of anthocyanin rich extract (ACRE), the
presumptive active ingredient of bilberries, in a controlled clinical trial in moderatesevere UC.

70 **Methods:** We performed a multicenter randomized, placebo-controlled, double-blind 71 study (planned initially for 100 patients; premature termination due to COVID-19 72 pandemic). Patients had moderate-severe active UC at screening (Mayo-score 6-12, 73 endoscopic sub-score at least 2) and were randomized at baseline (verum: placebo, 74 2:1). Continuation of all UC-directed stable medical therapy was allowed. Primary 75 endpoint was clinical response at week 8 (reduction of total Mayo-score at least 3 76 points). Biochemical (fecal calprotectin) and centrally-read endoscopic response were 77 amongst the secondary endpoints.

Results: Out of 48 patients screened in six Swiss trial centers, 34 were randomized.
Eighteen ACRE and eight placebo patients could be analyzed in the Per-Protocol-Set.
Half (9/18) of ACRE patients and 3/8 of placebo patients revealed clinical response at
week 8 (CI 0.399-6.963; p=0.278). An improvement of the Mayo-score was observed in
77.8% of ACRE treated patients (62.5% of placebo). Fecal calprotectin dropped from
1049+/-1139 to 557+/-756µg/g feces in the ACRE but not in the placebo group (947+/1039 to 1040+/-1179; p=0.035). Adverse events were rare.

85	<b>Conclusions:</b> ACRE therapy was not significantly superior to placebo at inducing a
86	clinical response. However, placebo response was unusual high. Moreover, there
87	was a significant calprotectin decrease at end of treatment, indicative of ACRE
88	biochemical efficacy in UC.
89	
90	Clinicaltrials.gov number: NCT04000139

91 Word count: 250

- 92 Keywords: Ulcerative colitis, anthocyanin rich extract (ACRE), inflammatory bowel
- 93 disease (IBD), complementary therapy, bilberries

#### 6

## 94 Study Highlights

95

- 96 What is known:
- 97 Dried bilberries have been reported to ameliorate active ulcerative colitis (UC)
- 98 in an uncontrolled pilot trial
- 99 Anthocyanins (flavonoids) are regarded to be the active anti-inflammatory
- 100 compound of bilberries
- An anthocyanin rich extract (ACRE) of bilberries was reported to ameliorate
- 102 colitis in mouse models

- 104 What is new here:
- In a multi-center randomized, double-blind, placebo controlled, parallel group
- study in patients with moderate to severe active UC, ACRE did not reach the
- 107 statistical endpoint of clinical response
- An unusually high placebo response was observed
- ACRE induced significant biochemical response with significant decrease in
- 110 calprotectin levels

## 111 Abbreviations

112	5-ASA, aminosalicylic acid (mesalazine); AC, anthocyanins; ACRE, anthocyanin rich
113	extract; CI, confidence interval; IBD, inflammatory bowel disease; IFN, interferon; IL,
114	interleukin; NF-кB, nuclear factor kappa B; NSAID, non-steroidal anti-inflammatory
115	drugs; OR, odds ratio; PPS, Per-Protocol-Set; ROS, reactive oxygen species; PRO,
116	patient reported outcome; QOL, quality of life; SIBDQ, short inflammatory bowel
117	disease questionnaire; TNF, tumor necrosis factor; TMS, total Mayo score; UC,
118	ulcerative colitis
119	
120	Word count (introduction to conclusion): 3377
121	
122	Introduction
123	Ulcerative colitis (UC) comprises along with Crohn's disease, the most common
124	forms of inflammatory bowel diseases (IBD). UC is an idiopathic, chronic relapsing
125	pathology of the colon affecting mainly young adults with a peak age range between
126	30 - 40 years and no gender predominance. Amongst the most typical symptoms are
127	severe, often bloody diarrhea, as well as abdominal discomfort. Although the clinical
128	course is variable, most patients suffer from recurrent flares and an unpredictable
129	disease course. <sup>1,2</sup> Quality of life may be severely impaired by persistent, frequent,
130	recurrent or waxing and waning symptoms. <sup>3</sup>

131 Despite the incurable nature of the disease, about two thirds of all UC patients132 with moderate disease activity can be successfully treated with mesalamine (5-

8

133	ASA). <sup>45</sup> Nevertheless, patients who do not achieve a sufficient response remain a
134	clinical challenge and up to 10% of all patients have to undergo colectomy in the
135	long-term, according to a very recent (2023) systematic review and meta-analysis. <sup>6</sup>
136	Although there is a plethora of potential effective drugs to treat UC, the overall
137	profile of those is far from being ideal: They harbor a considerable risk of short- and
138	long-term toxicity and numerous side effects. <sup>7-9</sup> Moreover, the annual costs of newer

139 treatment options (such as biologics and small molecules) are often high.<sup>10,11</sup> Most

140 importantly, even the latest treatments demonstrate efficiency in only a proportion of

141 UC patients.<sup>12</sup> Therefore, the development of further medical treatment options, with 142 favorable cost-benefit ratios and salutary side-effect profiles clearly represents an 143 urgent requirement for UC management. In this respect, herbal and natural 144 compound treatments constitute an appealing therapy option for UC patients. 145 Secondly, many Swiss patients long for more natural therapies. In this context, 146 several relevant studies report positive effect of curcuma<sup>13</sup> (Curcuma zedoaria, an 147 Indian spice), or of boswellia tree resin (*Boswellia serrata*) as well as aloe vera<sup>14,15</sup> on 148 UC patients.

In recent years there has been a rising interest in natural flavonoids, a subgroup of polyphenols, due to their beneficial effects on many conditions including cardiovascular disease and cancer. Anthocyanins (AC), compounds belonging to flavonoids, are abundant in red, blue and black berries, but also present in red wine and dark colored vegetables.<sup>16,17</sup>

9

154	AC have been associated with many protective biological effects, including
155	antioxidative, anticarcinogenic, antimicrobial, and anti-inflammatory properties. <sup>15,18,19</sup>
156	Due to their phenolic structure, AC exhibit anti-oxidative capacity in vivo as they
157	scavenge reactive oxygen species (ROS), <sup>18,20</sup> a classical effect of 5-ASA. <sup>21</sup> AC interrupt
158	pro-inflammatory signaling and are inhibitors of 5-lipoxygenase, a key enzyme
159	implicated in the arachidonic acid pathway, for the biosynthesis of active
160	leukotrienes (mainly via the unstable intermediate LTA4 to LTB4 and 5-HETE <sup>22,23</sup> ). In
161	the presence of flavonoids monocytes release less tumor necrosis factor (TNF) and
162	interleukin (IL) – $8.^{24}$ AC also impede activation of nuclear factor $\kappa B$ (NF- $\kappa B$ ) by
163	inhibition of proteasomal function. NF-κB as well as TNF and IL-8 constitute key
164	molecules orchestrating inflammation in IBD. <sup>15,25,26</sup>
165	Several research groups <sup>27-33</sup> including ours <sup>19,34-39</sup> reported a beneficial effect of
166	AC on preclinical models of UC. In view of the aforementioned results, the potential
167	of AC in a small uncontrolled pilot trial in 13 patients with UC was tested. <sup>40</sup> During
168	six weeks, patients received a daily AC-rich extract from bilberries (Vaccinium
169	myrtillus). Strikingly, clinical disease activity, as well endoscopic histological and

biochemical indicators for intestinal inflammation markedly improved. Side effectswere not observed. These data suggest AC as a potential adjunctive treatment option

172 in UC with very few, if any, side effects.<sup>40,41</sup>

This study aims to confirm these results in a multi-center double-blind, placebo
controlled, parallel group study to evaluate the efficacy, safety and tolerability of an
anthocyanin rich extract (ACRE) in subjects with moderately active UC.

#### 176 Materials and Methods

#### 177 Study Population

178 Patients with moderately or severely active UC were recruited between April 179 2019 and March 2021 at six IBD centers in Switzerland. Moderately or severely active 180 UC was defined as a Mayo score 6-12 with an endoscopic sub-score  $\geq$  2. Patients aged 181 18–70 years and diagnosed with UC since at least three months with the disease 182 extending at least 15 cm from the anal verge were included. Current oral or rectal 5-183 ASA/ sulfapyridine (SP) use or a history of oral or rectal 5-ASA/SP was allowed. 184 Furthermore, patients were eligible for the study if they fulfilled one of the following 185 criteria: a. Steroid intake up to 30 mg/day as well as a history of steroids dependency, 186 refractory, or intolerance, including no steroids treatment due to earlier side-effects. 187 OR b. Active disease despite induction therapy with 5-ASA agents, either 188 mesalamine (2-4.8 g/day) or sulfasalazine (4-6 g/day) administered for at least two 189 weeks. Topical treatment with 5-ASA was permissible but not sufficient for inclusion 190 in the study. OR c. Intolerance to oral 5-ASA or azathioprine. OR d. Active disease 191 despite thiopurine (adequately dosed according to treatment guidelines,<sup>42</sup> such as 2-3 192 mg/kg for azathioprine) or methotrexate treatment administered for at least 12 193 weeks. OR e. Active disease despite treatment with biologics effective in UC or 194 calcineurin inhibitors. No restrictions regarding other IBD therapies applied: Azathioprine/6-mercaptopurine was allowed, providing that the dose had been 195 196 stable for 8 weeks prior to baseline and had been initiated at least two months before 197 screening. TNF inhibitors (i.e. infliximab, adalimumab or golimumab) were allowed,

198 providing that the dose was unchanged for at least two months prior to baseline and 199 during the study treatment period. Vedolizumab and tofacitinib were allowed, 200 providing that the dose remained unchanged for at least two months prior to 201 baseline and during the study treatment period.

202 Exclusion criteria were a suspicion or diagnosis of Crohn's disease, ischemic 203 colitis, radiation colitis, indeterminate colitis, infectious colitis, diverticular disease 204 associated colitis, microscopic colitis, massive pseudopolyposis or a colonic stenosis 205 that could not be passed endoscopically, acute severe UC (as defined by Truelove and Witt's criteria<sup>43</sup>) and/or signs of systemic toxicity, UC limited to the rectum 206 207 (disease which extends <15 cm above the anal verge), long term treatment with 208 antibiotics or non-steroidal anti-inflammatory drugs (NSAID) within two weeks 209 prior to screening (one short treatment regime for antibiotics and occasional use of 210 NSAID was allowed), and within at least 30 days after last treatment of the 211 experimental product prior to enrolment history of malignancy, a history or presence 212 of any clinically significant disorder that, in the opinion of the investigator, could 213 impact on the patient's ability to adhere to the study protocol and study procedures 214 or would confound the study result or compromise patient safety.

All patients signed an informed consent form. The study was approved by the ethics committee of each center (BASEC2017-00156) and was conducted in accordance with the latest revision of Declaration of Helsinki<sup>44</sup> as well as the guidelines of Good Clinical Practice.<sup>45</sup> Moreover, the study was registered in the US online database of clinical research studies <u>ClinicalTrials.gov</u> (NCT04000139). All

12

authors were offered full access to the study data and reviewed and approved thefinal manuscript.

222

223 Study design and procedures

This was a multicenter randomized, double-blind, placebo-controlled trial. Patients with active moderate-severe UC despite state of the art 5—ASA, steroid, immunosuppressive of biological treatment were enrolled. Patients were randomized 2:1 (ACRE: placebo).

228 Upon study entry, all patients were instructed to continue their current 229 medications unchanged. They either received a standardized anthocyanin extract 230 (ACRE, referring to 800-1000 mg AC) administered per os three times daily or an optically identical placebo. Of note, similar or even lower AC doses have been 231 232 previously administered in human studies investigating (extra)intestinal beneficial actions and with favorable results.<sup>40,46,47</sup> As the ACRE capsule preparation contained 233 234 purple compounds (which could not be eliminated during the production process), 235 we added equally purple powder to the placebo capsule preparation, in order to 236 avoid any unblinding. The total duration of investigational product administration 237 amounted to eight weeks (56 days). All participating physicians were blinded to 238 treatment assignment throughout the study. After enrollment, patients underwent a 239 physical examination and laboratory blood tests including a complete blood count, 240 liver function tests, and C-reactive protein, which were performed at both baseline

13

and at the end of the phase protocol. Patients also underwent flexible
rectosigmoidoscopy at study entry (baseline) and at week 8, and endoscopic activity
was determined according to the endoscopic Mayo index sub-score<sup>48</sup> by a local and a
central reader.

245

246 Clinical Assessment and Trial End Points

Primary objective of the study was to evaluate the efficacy of the ACRE
preparation in subjects with moderately-severely active UC according to clinical,
endoscopic, histologic and biochemical markers. Secondary objectives included the
effects of ACRE on quality of life (QoL) as well as its safety.

251 (Mayo score 6-12, endoscopic sub-score  $\geq$  2) by comparing the clinical response 252 rate of subjects on an ACRE versus a placebo arm at week 8. As clinical response was 253 defined the reduction of total Mayo score (TMS)  $\geq$  3 points. Of note, the mentioned 254 cut-off for clinical response exhibits an established validity in several studies 255 previously.<sup>49-51</sup> Secondary objectives were the evaluation of 1) e ACRE-efficacy at 256 week 8 where clinical remission is defined as Mayo Score  $\leq 2$ , with no individual sub-257 score > 1; 2) ACRE safety and tolerability; 3) efficacy of an ACRE preparation in 258 subjects with moderately active UC compared to placebo in clinical remission, 259 clinical response and clinical symptoms; 4) ACRE efficacy in subjects with 260 moderately-severe active UC compared to placebo in endoscopic and histological remission and response; 5) quality of life (QOL) in patients of ACRE arm. 261

262	The primary endpoint was the clinical response at week 8 with clinical response
263	defined as a reduction of TMS by $\geq$ 3 points, similar to previous studies. <sup>49-51</sup>
264	Secondary endpoints were:
265	• The proportion of patients with symptomatic remission at week 8, defined by
266	the presence of both, a Mayo rectal bleeding sub-score of 0, and a stool frequency
267	subscore of 0 or 1 (with at least one point decrease from baseline, week 0), (patient
268	reported outcome) [PRO2]. <sup>52</sup>
269	• The proportion of patients without rectal bleeding at week 8, defined by a
270	Mayo rectal sub-score bleeding of 0.
271	• The proportion of patients with normal or enhanced stool frequency at week
272	8, defined by the Mayo stool frequency sub-score of 0 or 1 (with at least one point
273	decrease from baseline, week 0).
274	Other secondary endpoints assessed rectal bleeding, clinical response and
275	remission at week 4, durable remission (i.e. remission in weeks 8 and 12) and clinical
276	response at week 8 according to the modified Mayo-score, defined as a three point
277	and $\geq 30\%$ drop from baseline of the sum of the rectal bleeding, stool frequency,
278	endoscopy score (excluding friability) and physicians' global assessment (PGA).
279	• The proportion of patients with endoscopic remission at week 8, defined by a
280	modified Mayo endoscopic sub-score <sup>48</sup> of 0 or 1 (excluding friability).
281	• The proportion of patients with histological remission at week 8, defined by a
282	Geboes Index <sup>53</sup> of grade 0 or 1.

15

283	• Mean change in fecal calprotectin concentrations at weeks 1, 2, 4, and 8
284	compared to baseline, week 0.
285	• Mean change in steroid dosage compared to baseline for patients in remission
286	at week 8 to 12.
287	• Mean change in each of the short inflammatory bowel disease questionnaire
288	$(SIBDQ)^{54}$ sub-domains at week 8 compared to baseline (week 0).
289	The rate and time point of premature study withdrawals between both arms was also
290	explored in the data analysis.
291	Data acquisition and management were performed using OpenClinica
292	Community Edition, Version 3.14, and an OpenClinica eCRF.
293	
294	Analysis plan
295	
	A sample size of 112 patients was initially planned, leading to 100 patients
296	A sample size of 112 patients was initially planned, leading to 100 patients completing the study, assuming a drop-out rate of 12%, based on a frequentist power
296 297	A sample size of 112 patients was initially planned, leading to 100 patients completing the study, assuming a drop-out rate of 12%, based on a frequentist power calculation. According to our previous data, a clinical response was assumed in the
296 297 298	A sample size of 112 patients was initially planned, leading to 100 patients completing the study, assuming a drop-out rate of 12%, based on a frequentist power calculation. According to our previous data, a clinical response was assumed in the active treatment arm of 55% and in the placebo of 25%. For a 1:1 placebo vs. verum
296 297 298 299	A sample size of 112 patients was initially planned, leading to 100 patients completing the study, assuming a drop-out rate of 12%, based on a frequentist power calculation. According to our previous data, a clinical response was assumed in the active treatment arm of 55% and in the placebo of 25%. For a 1:1 placebo vs. verum randomization ratio, a patient number of 41 per group would be sufficient to achieve
296 297 298 299 300	A sample size of 112 patients was initially planned, leading to 100 patients completing the study, assuming a drop-out rate of 12%, based on a frequentist power calculation. According to our previous data, a clinical response was assumed in the active treatment arm of 55% and in the placebo of 25%. For a 1:1 placebo vs. verum randomization ratio, a patient number of 41 per group would be sufficient to achieve statistical significance with a power of 80%, assuming an $\alpha$ -error of maximal 5%. For

patients for both the groups. The analysis of the primary endpoint was conducted on

the FAS (full analysis set) and PPS (per-protocol set). Data analysis was performed

302

16

using SAS version 9.4 (Windows x64 version). Missing singular data items were
carried forward. This did not apply, of course, when entire visits were missed (p.ex.,
in the case of premature study termination).

307

308 RESULTS

309 Study Population

310 Out of 48 patients screened in a total of six Swiss trial centers, 34 (70.9%) were 311 enrolled and randomized, whereas 14 (29.1%; 4 females and 10 males) were 312 considered screening failures.

Five randomized ACRE and two placebo patients prematurely terminated the study before the scheduled end of treatment at visit 3 (week 8). One ACRE patient started prednisone (20 mg/day) treatment at visit 1 and was excluded from all analyses for violation of the protocol. Thus, 18 ACRE and eight placebo patients could be analyzed in the per-protocol-set (PPS).

At screening, the majority of patients (69.2%) were on concomitant steroid medication. 16.7% in the bilberry group and 25% in the placebo group received anti-TNF treatment. Patient baseline characteristics are enclosed in Table 1.

321

### 322 Efficacy Analysis

## 323 Primary endpoint (Clinical Response at Week 8)

17

324	Clinical response at week 8 was achieved in nine out of 18 ACRE patients and
325	three out of eight (3/8) placebo patients (Figure 1, Table 2). This corresponds to an
326	odds ratio (OR) for response of 1.667 in favor of ACRE arm, with a 90% confidence
327	interval (CI) between $0.399 - 6.963$ and a one-sided $p = 0.278$ in the logistic analysis
328	and the primary endpoint was not met.
329	In a post-hoc analysis, mean reduction in partial Mayo score was $2.61 \pm 2.79$ for
330	ACRE arm and $2.00 \pm 3.07$ for placebo arm (Figure 2, not significant). Assuming a
331	normal distribution, the 90% CI of the change in TMS does not include the point 0
332	(no change) for ACRE while this point is within the 90% CI for placebo arm.
333	An interesting finding of this study is the unusual high percentage of placebo
334	response, i.e., 37.5% for the clinical response and 62.5% for the Mayo score
335	amelioration.
000	

336

# 337 <u>Secondary endpoints</u>

The secondary endpoint of clinical remission at week 8 was achieved in 9/18 patients of ACRE arm versus 3/8 patients of placebo arm (CI 0.399–6.963; p=0.278, not significant), even though we noted numerical improvements in both individual subscores rectal bleeding and stool frequency (Table 3).

342

### 343 Endoscopic Remission at Week 8

18

344	The endoscopic findings (with central reading and site reading) yielded similar
345	results, which are inconclusive and fail to demonstrate therapeutic effects.

346

## 347 <u>Change in fecal calprotectin Endpoint vs. Baseline</u>

Fecal calprotectin remained practically the same in placebo group between baseline and end of experiment values ( $947\pm1039$  to  $1040\pm1179$ ) whereas it significantly decreased for ACRE group ( $1049\pm1139$  to  $557\pm756\mu g/g$ , p=0.035). No difference for any of the other secondary endpoints was noted.

#### 352 <u>Safety Analysis</u>

Among the treated patients, a total of 68 adverse events, two of which were regarded to be serious, were recorded in 29 patients. All serious adverse events were assessed as unrelated to study medication. One patient developed an infectious colitis before enrolment. Another individual experienced an exacerbation of UC, which required hospitalization. Overall ACRE was very well tolerated and no new safety signals were detected.

359

### 360 DISCUSSION

In this multi-center, randomized, double-blind and placebo controlled, phase IIa study, we aimed to evaluate the efficacy, safety as well as tolerability of ACRE in patients with UC. Although the clinical response at the end of the study did not

19

364 differ between the two arms, a statistically significant difference was recorded in the365 secondary endpoint of fecal calprotectin.

Fecal calprotectin serves as a valuable indicator of inflammation within the intestines<sup>55,56</sup> and has become an integral component of routine testing for diagnosing and monitoring IBD. According to a recent meta-analysis, fecal calprotectin is an inexpensive, valuable and rather accurate predictor IBD relapses.<sup>55</sup> Additionally, further evidence has established fecal calprotectin as a useful marker recognizing an early response to IBD treatment, since it correlates robustly with serologic markers, endoscopic inflammation and disease activity indices of IBD subjects.<sup>56</sup>

As aforementioned, our research group firstly reported in 2013 within a pilot study<sup>40</sup> the beneficial effects of bilberries on UC patients, results that we could also confirm later on.<sup>35</sup> Comparable beneficial results of have been demonstrated independently by Kropat et al.<sup>57</sup> An ongoing relevant Australian clinical trial with double-blind, randomized, controlled, multi-arm design has been recently announced,<sup>58</sup> investigating the effect of administration of AC and/or multi-strain probiotics on UC patients.

In respect to the available *in vivo* preclinical scientific evidence, we reported as early as 2011 that bilberries and their AC positively impacted on an experimental acute and chronic colitis mouse model.<sup>19</sup> Later, and again by utilizing the same murine model mimicking human UC and UC-associated cancer, we demonstrated<sup>36</sup> that AC ingestion could avert the onset and progression of murine tumors in colon.

20

385 Comparable favorable results of AC on IBD murine models have been henceforth
386 published by other study groups.<sup>29-31,59,60</sup>

387 Interestingly, there is emerging evidence, that AC administration offers 388 beneficial effects beyond IBD to further intestinal diseases such as colorectal 389 carcinoma and irritable bowel syndrome.<sup>61</sup> Bilberries and/or AC have also been 390 investigated as a treatment targeting extraintestinal organs in various settings and 391 have shown a positive impact in clinical trials, among others, for vascular health and 392 cognitive function,<sup>46</sup> or metabolic syndrome and associated conditions.<sup>26</sup> A very 393 recent US study with a large sample of patients (n = 37,232) found a direct inverse 394 relationship between overall mortality risk and consumption of diverse berries and 395 their containing flavonoids.<sup>17</sup>

One of the reasons for the health-promoting effects of AC is regarded to be their antioxidant effect owing to their phenolic structure, enabling them to neutralize ROS.<sup>39</sup> Additionally, AC display antimicrobial effects, such as against *Bacillus cereus*, and *Helicobacter pylori*.<sup>62</sup> They also reduce the expression of various genes involved in atherosclerosis formation in animal models.<sup>63</sup> Moreover, AC inhibit inflammationpromoting pathways in immune cells.<sup>39</sup>

As stressed in the results section, an unusual high percentage of placebo response for the Mayo score improvement was noted. In this respect, a Cochrane meta-analysis<sup>64</sup> of 61 studies estimated the placebo response and remission rates of induction treatment for UC (adult population) to be 33% and 12%, respectively. Placebo effect and rates of remission fluctuated based on several factors, including

21

the severity of endoscopic disease and the rectal bleeding score upon trial initiation,
the type of medication used, duration of the disease, and the specific time when the
primary outcome was assessed.<sup>64</sup>

410 In a second more recent systematic review with meta-analysis (2022), clinical, 411 endoscopic, histological and safety placebo rates in induction and maintenance trials 412 of UC have been evaluated.<sup>65</sup> After considering a total number of 119 trials (of which 413 92 in induction and 27 in maintenance) the abovementioned parameters were for the 414 induction studies 11%, 19% and 15%, respectively. Again, the authors deduced 415 placebo response rates observed in trials for UC differ depended on the endpoint 416 evaluated, whether it pertains to response assessment or achieving remission, and 417 whether the trial focuses on induction or maintenance.

The purple color of the drug as well as the placebo might be partially 418 419 responsible for the high placebo rates. As a possible interpretation of this unexpected 420 placebo effect, studies conducted in the past have identified the color of the placebo 421 pills to correlate with outcomes.<sup>66-68</sup> Thus, the colors of drugs may impact how their 422 effects are perceived and may also play a role in their effectiveness. Additionally, 423 there appears to be a connection between the coloring of drugs that affect the central 424 nervous system and the conditions they are prescribed for. In this context there is 425 evidence that red, yellow, and orange color of pills are linked to a stimulant effect, 426 whereas blue, purple and green are connected to a tranquillizing – sedative effect.<sup>66-68</sup>

427 The strengths of this study includes the double-blinded, randomized and multi-428 center study design. The low number of participants is the main limitation of this

429	study, this is at least partially due to restriction during the COVID-19 pandemic.
430	since individual patients, as aforementioned commented, have impacted relevantly
431	the outcome. However, this did not prevent a statistical significance for fecal
432	calprotectin between the two study arms.
433	
434	CONCLUSION
435	In conclusion, ACRE did not induce clinical response at 8 weeks in patients
436	with moderate to severe UC. However, due to limitations to recruit a large sample
437	size, limiting some analyses, significant decreases in fecal calprotectin levels upon
438	ACRE treatment were noted.
439	
440	CONFLICTS OF INTEREST
441	PS received consulting fees from Pfizer, Abbvie, Takeda and Janssen-Cilag and travel
442	support from Falk, UCB and Pfizer.
443	LB reports fees for consulting/advisory board from Abbvie, MSD, Vifor, Falk, Esocap,
444	Calypso, Ferring, Pfizer, Shire, Takeda, Janssen, Ewopharma.
445	GR declares consulting fees from Abbvie, Augurix, BMS, Boehringer, Calypso, Celgene,
446	FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche,
447	UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; speaker's honoraria from Astra
448	Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor and Zeller;
449	and grants support from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD,
450	Novartis, Pfizer, Roche, Takeda, Tillots, UCB and Zeller.

23

451	BM reports traveling fees from Takeda, Vifor, Gilead and MSD. BM received fees as a
452	speaker from Takeda. BM has served at an advisory board for Abbvie, Gilead,
453	Takeda and BMS. BM has received research grants from MSD, BMS and Nestlé
454	unrelated to the submitted work.
455	MD reports traveling fees from Takeda, FALK, Abbvie as well as consulting fees
456	from Takeda.
457	Rest of the authors declare no compelling conflict of interests.
458	ACKNOWLEDGEMENTS
459	The authors wish to thank all the patients for their cooperation as well as their
460	families for their support during this endeavor.
461	
162	PEEPENCES

### 462 **REFERENCES**

463 464 465 466	1.	Lang BM, Ledergerber M, Jordi SBU, et al. Because I'm happy - positive affect and its predictive value for future disease activity in patients with inflammatory bowel diseases: a retrospective cohort study. <i>Therap Adv Gastroenterol.</i> 2023;16:17562848231179335.
467	2.	Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis.
468		<i>Lancet.</i> 2017;389(10080):1756-1770.
469	3.	Norouzkhani N, Faramarzi M, Ghodousi Moghadam S, et al. Identification of the
470		informational and supportive needs of patients diagnosed with inflammatory bowel
471		disease: a scoping review. Front Psychol. 2023;14:1055449.
472	4.	Awadhi SA, Alboraie M, Albaba EA, et al. Treatment of Patients with Mild to Moderate
473		Ulcerative Colitis: A Middle East Expert Consensus. J Clin Med. 2023;12(21).
474	5.	Harbord M, Eliakim R, Bettenworth D, et al. Third European Evidence-based
475		Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current
476		Management. J Crohns Colitis. 2017;11(7):769-784.
477	6.	Dai N, Haidar O, Askari A, Segal JP. Colectomy rates in ulcerative colitis: A
478		systematic review and meta-analysis. <i>Dig Liver Dis</i> . 2023;55(1):13-20.
479	7.	Wang K, Zhu Y, Liu K, Zhu H, Ouyang M. Adverse events of biologic or small
480		molecule therapies in clinical trials for inflammatory bowel disease: A systematic
481		review and meta-analysis. <i>Heliyon.</i> 2024;10(4):e25357.
482	8.	Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD.
483		Best Pract Res Člin Gastroenterol. 2010;24(2):167-182.

40.4	0	Lawren T. Davila A. Dallaria C. et al. Davilità hundan et adversa mantiana ta
484	9.	Larussa T, Basile A, Pallella C, et al. Real-life burden of adverse reactions to
485		biological therapy in inflammatory bowel disease: a single-centre prospective case
486	4.0	series. Med Pharm Rep. 2021;94(3):289-297.
487	10.	Alulis S, Vadstrup K, Olsen J, et al. The cost burden of Crohn's disease and
488		ulcerative colitis depending on biologic treatment status - a Danish register-based
489		study. BMC Health Serv Res. 2021;21(1):836.
490	11.	van Linschoten RCA, Visser E, Niehot CD, et al. Systematic review: societal cost of
491		illness of inflammatory bowel disease is increasing due to biologics and varies
492		between continents. Aliment Pharmacol Ther. 2021;54(3):234-248.
493	12.	Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics
494		and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a
495		systematic review and network meta-analysis. Lancet Gastroenterol Hepatol.
496		2022;7(2):161-170.
497	13.	Pituch-Zdanowska A, Dembinski L, Banaszkiewicz A. Old but Fancy: Curcumin in
498		Ulcerative Colitis-Current Overview. Nutrients, 2022:14(24).
499	14.	Gupta M. Mishra V. Gulati M. et al. Natural compounds as safe therapeutic options
500		for ulcerative colitis Inflammonharmacology 2022:30(2):397-434
501	15	Triantafyllidi A Xanthos T Papalois A Triantafillidis .IK Herbal and plant therapy in
502	10.	patients with inflammatory howel disease Ann Gastroenterol 2015:28(2):210-220
502	16	Lang Y. Gao N. Zang Z. et al. Classification and antioxidant assays of polyphenols: a
504	10.	review lournal of Future Foods $2024:A(3):103-204$
505	17	Zhang L. Muscat JE. Chinchilli VM. Kris-Etherton PM. Al-Shaar L. Richie, IP
505	17.	Consumption of Berries and Elayonoids in Relation to Mortality in NHANES 1000-
500		
507	10	2014. J Null. 2024, 134(2). 734-743. Kras I. Milankovia D. Anthoovaning: From Sources and Picovailability to
500	10.	Cardiovascular Health Papafite and Malacular Mashanisms of Action J Agric Food
509		Cham 2010.67(7):1771 1792
510	10	Diberger U. Ochme A. Hefmann C. et al. Bilberries and their antheovening amplicates
511	19.	Piperger H, Centre A, Hormann C, et al. Dilbernes and their anthocyanins amenorate
512	20	Experimental collis. Mol Null Food Res. 2011,55(11).1724-1729.
515	20.	Pena N, Martin J, Asuero AG. State of the Art of Anthocyanins. Antioxidant Activity,
514 515		(Peacl) 2020.0(5)
515	04	(Dasel). 2020,9(5).
510	21.	Annielt-Ronne I, Nielsen OH, Christensen A, Langholz E, Binder V, Rils P. Cillical
517		evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid.
518	00	Gastroenterology. 1990;98(5 Pt 1):1162-1169.
519	22.	Nielsen OH, Buknave K, Eimgreen J, Annielt-Ronne I. Innibition of 5-lipoxygenase
520		pathway of arachidonic acid metabolism in numan neutrophils by sulfasalazine and 5-
521		aminosalicylic acid. Dig Dis Sci. 1987;32(6):577-582.
522	23.	Aligayer H, Stenson WF. A comparison of effects of sulfasalazine and its metabolites
523		on the metabolism of endogenous vs. exogenous arachidonic acid.
524	~ 1	Immunopharmacology. 1988;15(1):39-46.
525	24.	Al-Khayri JM, Sahana GR, Nagella P, Joseph BV, Alessa FM, Al-Mssallem MQ.
526		Flavonoids as Potential Anti-Inflammatory Molecules: A Review. <i>Molecules</i> .
527		2022;27(9).
528	25.	Sahoo DK, Heilmann RM, Paital B, et al. Oxidative stress, hormones, and effects of
529		natural antioxidants on intestinal inflammation in inflammatory bowel disease. Front
530		Endocrinol (Lausanne). 2023;14:1217165.
531	26.	Sharma A, Lee HJ. Anti-Inflammatory Activity of Bilberry (Vaccinium myrtillus L.). Curr
532		Issues Mol Biol. 2022;44(10):4570-4583.
533	27.	Akiyama S, Nesumi A, Maeda-Yamamoto M, Uehara M, Murakami A. Effects of
534		anthocyanin-rich tea "Sunrouge" on dextran sodium sulfate-induced colitis in mice.
535		Biofactors. 2012;38(3):226-233.
536	28.	Li L, Wang L, Wu Z, et al. Anthocyanin-rich fractions from red raspberries attenuate
537		inflammation in both RAW264.7 macrophages and a mouse model of colitis. Sci Rep.
538		2014;4:6234.

539 540 541	29.	Zhao L, Zhang Y, Liu G, Hao S, Wang C, Wang Y. Black rice anthocyanin-rich extract and rosmarinic acid, alone and in combination, protect against DSS-induced colitis in mice. <i>Food Funct</i> , 2018:9(5):2796-2808.
542 543 544	30.	Peng Y, Yan Y, Wan P, et al. Gut microbiota modulation and anti-inflammatory properties of anthocyanins from the fruits of Lycium ruthenicum Murray in dextran sodium sulfate-induced colitis in mice. <i>Free Radic Biol Med.</i> 2019;136:96-108.
545 546	31.	Li S, Wang T, Wu B, et al. Anthocyanin-containing purple potatoes ameliorate DSS- induced colitis in mice. <i>J Nutr Biochem.</i> 2021;93:108616.
547 548 549	32.	Mu J, Xu J, Wang L, Chen C, Chen P. Anti-inflammatory effects of purple sweet potato anthocyanin extract in DSS-induced colitis: modulation of commensal bacteria and attenuated bacterial intestinal infection. <i>Food Funct.</i> 2021;12(22):11503-11514.
550 551 552	33.	Zhang G, Gu Y, Dai X. Protective Effect of Bilberry Anthocyanin Extracts on Dextran Sulfate Sodium-Induced Intestinal Damage in Drosophila melanogaster. <i>Nutrients.</i> 2022;14(14).
553 554	34.	Roth S, Spalinger MR, Muller I, Lang S, Rogler G, Scharl M. Bilberry-derived anthocyanins prevent IFN-gamma-induced pro-inflammatory signalling and cytokine
555 556 557 558	35.	Roth S, Spalinger MR, Gottier C, et al. Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis. <i>PLoS One.</i> 2016;11(5):e0154817.
559 560	36.	Lippert E, Ruemmele P, Obermeier F, et al. Anthocyanins Prevent Colorectal Cancer Development in a Mouse Model. <i>Digestion.</i> 2017;95(4):275-280.
561 562	37.	Dreiseitel A, Schreier P, Oehme A, et al. Anthocyanins and anthocyanidins are poor inhibitors of CYP2D6. <i>Methods Find Exp Clin Pharmacol.</i> 2009;31(1):3-9.
563 564 565	38.	Dreiseitel A, Schreier P, Oehme A, et al. Inhibition of proteasome activity by anthocyanins and anthocyanidins. <i>Biochem Biophys Res Commun.</i> 2008;372(1):57-61.
566 567 568	39.	Scharl M, Rogler G, Biedermann L. Anthocyane, Heidelbeeren und Curcuma: Wirksame Therapeutika bei Darmentzündungen? <i>Schweizerische Zeitschrift für</i> <i>Ganzheitsmedizin / Swiss Journal of Integrative Medicine</i> , 2017;29(3):137-140.
569 570 571	40.	Biedermann L, Mwinyi J, Scharl M, et al. Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - an open pilot study. <i>J Crohns Colitis.</i> 2013;7(4):271-279
572 573	41.	Li S, Wu B, Fu W, Reddivari L. The Anti-inflammatory Effects of Dietary Anthocyanins against Ulcerative Colitis. <i>Int J Mol Sci.</i> 2019;20(10).
574 575	42.	Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. <i>Am J Gastroenterol.</i> 2019;114(3):384-413.
576 577	43.	Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. <i>Br Med J.</i> 1955;2(4947):1041-1048.
578 579	44.	World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. <i>JAMA</i> . 2013;310(20):2191-2194.
580 581 582	45.	(R3) IE. Guideline on good clinical practice (GCP) Step 2b. 2023; <u>https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice-scientific-guideline</u> . Accessed 15.03.2024.
583 584 585	46.	Wood E, Hein S, Mesnage R, et al. Wild blueberry (poly)phenols can improve vascular function and cognitive performance in healthy older individuals: a double- blind randomized controlled trial. <i>Am. J Clin Nutr.</i> 2023;117(6):1306-1319
586 587	47.	Zhang H, Xu Z, Zhao H, et al. Anthocyanin supplementation improves anti-oxidative and anti-inflammatory capacity in a dose-response manner in subjects with
588 589 590 591	48.	dyslipidemia. <i>Redox Biol.</i> 2020;32:101474. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. <i>N Engl J Med.</i> 1987;317(26):1625-1629
592 593 594	49.	Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. <i>Inflamm Bowel Dis.</i> 2008;14(12):1660-1666.

595	50.	Sandborn WJ, Sands BE, Vermeire S, et al. Modified Mayo score versus Mayo score
596		for evaluation of treatment efficacy in patients with ulcerative colitis: data from the
597		tofacitinib OCTAVE program. Therap Adv Gastroenterol.
598		2022;15:17562848221136331.
599	51.	Sandborn WJ, Cyrille M, Hansen MB, et al. Efficacy and Safety of Abrilumab in a
600		Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.
601		Gastroenterology. 2019;156(4):946-957 e918.
602	52.	Bewtra M, Brensinger CM, Tomov VT, et al. An optimized patient-reported ulcerative
603		colitis disease activity measure derived from the Mayo score and the simple clinical
604		colitis activity index. Inflamm Bowel Dis. 2014;20(6):1070-1078.
605	53.	Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Lofberg R. A reproducible grading
606		scale for histological assessment of inflammation in ulcerative colitis. Gut.
607		2000;47(3):404-409.
608	54.	Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease
609		Questionnaire: a quality of life instrument for community physicians managing
610		inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse
611		Prevention Trial. Am J Gastroenterol. 1996:91(8):1571-1578.
612	55.	Shi JT, Chen N, Xu J, et al. Diagnostic Accuracy of Fecal Calprotectin for Predicting
613		Relapse in Inflammatory Bowel Disease: A Meta-Analysis. J Clin Med. 2023;12(3).
614	56.	Lee YW. Lee KM. Lee JM. et al. The usefulness of fecal calprotectin in assessing
615		inflammatory bowel disease activity. Korean J Intern Med. 2019:34(1):72-80.
616	57.	Kropat C. Mueller D. Boettler U. et al. Modulation of Nrf2-dependent gene
617		transcription by bilberry anthocyanins in vivo. Mol Nutr Food Res. 2013:57(3):545-
618		550.
619	58.	Cosier D. Lambert K. Batterham M. Sanderson-Smith M. Mansfield KJ. Charlton K.
620		The INHABIT (synergistic effect of aNtHocyAnin and proBloTics in) Inflammatory
621		Bowel Disease trial: a study protocol for a double-blind, randomised, controlled, multi-
622		arm trial. J Nutr Sci. 2024;13:e1.
623	59.	Chen J, Jiang F, Xu N, et al. Anthocyanin Extracted from Purple Sweet Potato
624		Alleviates Dextran Sulfate Sodium-Induced Colitis in Mice by Suppressing Pyroptosis
625		and Altering Intestinal Flora Structure. J Med Food. 2024;27(2):110-122.
626	60.	Mo J, Ni J, Zhang M, et al. Mulberry Anthocyanins Ameliorate DSS-Induced
627		Ulcerative Colitis by Improving Intestinal Barrier Function and Modulating Gut
628		Microbiota. Antioxidants (Basel). 2022;11(9).
629	61.	Liu Y. Fernandes I. Mateus N. Oliveira H. Han F. The Role of Anthocyanins in
630	-	Alleviating Intestinal Diseases: A Mini Review. J Agric Food Chem. 2024.
631	62.	Nohynek LJ, Alakomi HL, Kahkonen MP, et al. Berry phenolics: antimicrobial
632		properties and mechanisms of action against severe human pathogens. Nutr Cancer.
633		2006;54(1):18-32.
634	63.	Mauray A, Felgines C, Morand C, Mazur A, Scalbert A, Milenkovic D. Bilberry
635		anthocyanin-rich extract alters expression of genes related to atherosclerosis
636		development in aorta of apo E-deficient mice. Nutr Metab Cardiovasc Dis.
637		2012;22(1):72-80.
638	64.	Jairath V, Zou GY, Parker CE, et al. Placebo response and remission rates in
639		randomised trials of induction and maintenance therapy for ulcerative colitis.
640		Cochrane Database Syst Rev. 2017;9(9):CD011572.
641	65.	Sedano R, Hogan M, Nguyen TM, et al. Systematic Review and Meta-Analysis:
642		Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and
643		Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2022;16(2):224-243.
644	66.	Bhugra D, Ventriglio A, Till A, Malhi G. Colour, culture and placebo response. Int J
645		Soc Psychiatry. 2015;61(6):615-617.
646	67.	de Craen AJ, Roos PJ, de Vries AL, Kleijnen J. Effect of colour of drugs: systematic
647		review of perceived effect of drugs and of their effectiveness. BMJ.
648		1996;313(7072):1624-1626.
649	68.	Jacobs KW, Nordan FM. Classification of placebo drugs: effect of color. Percept Mot
650		Skills. 1979;49(2):367-372.



652

653



Figure 1: Clinical Response of both arms (ACRE vs placebo) at Week 8 after
baseline. ACRE, Anthocyanin rich extract. Numbers within the bars indicate
the absolute number of patients.



659 Figure 2: post-hoc analysis, mean reduction in partial Mayo score, with 90%
660 confidence interval for mean, albeit without statistical significance. ACRE,
661 anthocyanin rich extract.



### 662

**663** Figure 3: Calprotectin levels  $(\mu g/g)$  over the observation period between two arms.

664 ACRE, anthocyanin rich extract.

### 665

## 666 Table 1: Baseline characteristics

	ACRE	Placebo	All patients
Gender (f/m)	10/14	5/5	15/19
All randomized			
patients			
Gender (f/m)	8/10	4/4	12/14
Per protocol set			
Total Mayo Score	$8.43 \pm 1.31$	$8.50 \pm 1.90$	
(Mean value ± SD) at			
Screening			
Steroids/no steroids	14 (77.8%)	4 (50.0%)	18 (69.2%)
	4 (22.2%)	4 (50.0%)	8 (30.8%)
TNF tx/no TNF tx	3 (16.7%)	2 (25.0%)	5 (19.2%)
	15 (83.3%)	6 (75.0%)	21 (80.8%)

30

# 667 ACRE, anthocyanin rich extract; f/m, female/male; SD, standard deviation; TNF,

	Treatment	p-value
668	tumor necrosis factor; tx, treatment	

669

## 670 Table 2: Categorized Change in Total Mayo Score

Change in Total Mayo Sco	re	Treatment		
	ACR	E	Placebo	D
	Patients	%	Patients	%
Clinical response	9	50.0%	3	37.5
Improved	5	27.8%	2	25.0
Unchanged	2	11.1%	2	25.0
Worsened	2	11.1%	1	12.5
All	18	100.0%	8	100.0
671 ACRE, anthocyanin rich extr	act			
672				
673				
075				
674				
675				
675				
676				
077				
677				
678				
679				
680				
681				
682				
683				
684				

	ACRE		Plac	Placebo	
	Patients	%	Patients	%	
Symptomatic remission	8/18	44.4	3/8	37.5	0.371
No bleeding	13/18	72.2	4/8	50.0	0.139
Normal stool frequency	10/18	11.1	4/8	50.0	0.397
Endoscopic remission	4/18	22.2	2/8	25	0.412

- 685 Table 3: Categorized Changes at week 8
- 686 ACRE, anthocyanin rich extract